Form 4: Nurix Legal Chief Granted Stock Options, RSUs

Nurix Therapeutics' Chief Legal Officer, Christine Ring, was granted 93,750 stock options and 42,875 restricted stock units.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), was granted derivative securities on February 10, 2026.
• The grants include 93,750 employee stock options with an exercise price of $16.45 per share.
• These stock options will vest as to 1/36 of the total shares monthly, commencing March 10, 2026, and will be fully vested by February 9, 2029, contingent on continued service.
• The stock options have an expiration date of February 9, 2036.
• Additionally, 42,875 Restricted Stock Units (RSUs) were granted, with each RSU representing a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, also subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for executive retention and alignment, reflecting standard compensation practices that incentivize long-term commitment and performance.

Positives

• The grant of stock options and restricted stock units aligns the Chief Legal Officer's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining key executives in the biotechnology industry.

Future Outlook

The multi-year vesting schedules for both the stock options and restricted stock units indicate an expectation of continued service from the Chief Legal Officer, aligning future compensation with long-term company performance.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and restricted stock units, are a common and effective component of executive compensation packages in the biotechnology sector. This practice aims to attract, retain, and motivate key talent by linking their financial success directly to the company's long-term share price performance and strategic achievements.

Comparison to Industry Standards

• StockSavvy.ai notes that the structure of these grants, with multi-year vesting schedules (3 years for options, 3 years for RSUs), is consistent with typical executive compensation packages in the biotechnology sector, similar to practices observed at companies like Moderna or BioNTech for retaining key talent.
• The combination of stock options and RSUs is a common approach in the industry to provide both upside potential and retention value, balancing performance incentives with long-term commitment.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the Chief Legal Officer's interests with shareholder value creation over the long term.
• Employees: This type of executive compensation can set a precedent or standard for other key employees, potentially impacting overall compensation philosophy.

Next Steps

• Christine Ring's continued provision of service to Nurix Therapeutics, Inc. is required for the vesting of both stock options and restricted stock units.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Form 4, stock option, RSU, equity grant, executive compensation, Christine Ring